ERBB2 status is typically determined using laboratory tests such as Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH). IHC assesses the presence of HER2 protein on the surface of cancer cells, while FISH tests for amplification of the ERBB2 gene. Both tests are necessary to accurately identify HER2 status and guide treatment decisions.
